Insider trading

Period: 120 months Stock: MDGL + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

129 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

129 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

129 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

129 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
129 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
129 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

129 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
3 Mar 2025
Kelley Shannon T General Counsel
Sold on a plan
$139.03K 415 at 335.00
5.4%
Planned (10b5-1)
28 Feb 2025
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 2×
$418.49K 1,227 at 341.07
24.8%
Not planned
27 Feb 2025
BATE KENNETH Director
Sold at will 9×
$7.13M 20,000 at 356.44
91.3%
Sold half or more
27 Feb 2025
Daly James M Director
Sold at will 3×
$5.38M 15,470 at 347.45
89.0%
Sold half or more
24 Jan 2025
Sibold William John President and CEO
Sold at will
$531.02K 1,584 at 335.24
2.8%
Not planned
24 Jan 2025
Taub Rebecca Pres., R&D, and CMO
Sold at will
$217.24K 648 at 335.24
0.1%
Not planned
24 Jan 2025
Huntsman Carole Chief Commercial Officer
Sold at will
$116.33K 347 at 335.24
3.2%
Not planned
24 Jan 2025
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will
$34.53K 103 at 335.24
2.0%
Not planned
17 Jan 2025
Taub Rebecca Pres., R&D, and CMO
Sold at will
$461.79K 1,689 at 273.41
0.4%
Not planned
17 Jan 2025
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will
$120.85K 442 at 273.41
8.0%
Not planned
17 Jan 2025
Kelley Shannon T General Counsel
Sold at will
$75.73K 277 at 273.41
3.5%
Not planned
3 Dec 2024
CRAVES FRED B Director · indirect
Sold at will 2×
$1.14M 3,600 at 315.31
24.7%
Not planned
25 Nov 2024
CRAVES FRED B Director · indirect
Sold at will 2×
$1.19M 3,400 at 350.30
18.9%
Not planned
21 Nov 2024
Huntsman Carole Chief Commercial Officer
Sold at will
$218.04K 688 at 316.92
6.0%
Not planned
7 Nov 2024
Levy Richard S Director
Sold on a plan
$1.75M 5,000 at 350.00
31.2%
Planned (10b5-1)
1 Nov 2024
Levy Richard S Director
Sold on a plan 4×
$1.50M 5,000 at 300.94
31.2%
Planned (10b5-1)
9 Sep 2024
Sibold William John President and CEO
Sold at will
$1.55M 6,363 at 243.83
10.2%
Not planned
14 Jun 2024
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will
$532.00K 1,900 at 280.00
25.7%
Not planned
12 Jun 2024
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will
$570.00K 2,000 at 285.00
26.7%
Not planned
21 May 2024
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will
$239.67K 1,036 at 231.34
15.9%
Not planned
14 May 2024
CRAVES FRED B Director
Sold on a plan 10×
$4.79M 22,489 at 212.88
5.2%
Planned (10b5-1)
8 Apr 2024
FRIEDMAN PAUL A Director
Sold on a plan 7×
$6.47M 26,270 at 246.19
12.4%
Planned (10b5-1)
8 Apr 2024
Taub Rebecca Pres., R&D, and CMO
Sold on a plan 6×
$658.26K 2,676 at 245.99
0.6%
Planned (10b5-1)
5 Apr 2024
FRIEDMAN PAUL A Director
Sold on a plan 7×
$6.72M 27,613 at 243.40
12.9%
Planned (10b5-1)
5 Apr 2024
Taub Rebecca Pres., R&D, and CMO
Sold on a plan 6×
$6.69M 27,506 at 243.36
5.7%
Planned (10b5-1)
4 Apr 2024
FRIEDMAN PAUL A Director
Sold on a plan 8×
$4.55M 18,710 at 242.96
9.2%
Planned (10b5-1)
4 Apr 2024
Taub Rebecca Pres., R&D, and CMO
Sold on a plan 8×
$4.50M 18,537 at 242.91
3.9%
Planned (10b5-1)
3 Apr 2024
Taub Rebecca Pres., R&D, and CMO
Sold on a plan 5×
$6.83M 27,845 at 245.14
5.7%
Planned (10b5-1)
3 Apr 2024
FRIEDMAN PAUL A Director
Sold on a plan 5×
$6.72M 27,407 at 245.12
12.9%
Planned (10b5-1)
2 Apr 2024
BATE KENNETH Director
Sold on a plan 7×
$2.74M 11,212 at 244.49
90.3%
Sold half or more
2 Apr 2024
Daly James M Director
Sold on a plan 6×
$2.67M 10,912 at 244.51
90.1%
Sold half or more
1 Apr 2024
Daly James M Director
Sold on a plan 10×
$5.55M 21,577 at 257.24
94.7%
Sold half or more
1 Apr 2024
BATE KENNETH Director
Sold on a plan 10×
$5.47M 21,277 at 257.26
94.7%
Sold half or more
1 Apr 2024
Levy Richard S Director
Sold on a plan 6×
$2.83M 11,000 at 257.48
51.6%
Sold half or more
15 Dec 2023
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 2×
$477.00K 2,000 at 238.50
26.1%
Not planned
14 Dec 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 8×
$4.71M 20,633 at 228.32
1.2%
14 Dec 2023
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 2×
$465.00K 2,000 at 232.50
26.1%
Not planned
13 Dec 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 16×
$17.81M 81,159 at 219.39
4.8%
Largest buy in 3 yrs
13 Dec 2023
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 2×
$563.50K 2,500 at 225.40
30.6%
Not planned
12 Dec 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 30×
$7.55M 34,578 at 218.31
2.1%
12 Dec 2023
Waltermire Robert E. Senior VP, Chief Pharma Dev.
Sold at will 2×
$283.20K 1,300 at 217.85
18.7%
Not planned
5 Dec 2023
Lynch Brian Joseph SVP and General Counsel
Sold at will
$227.33K 1,000 at 227.33
6.2%
Not planned
4 Dec 2023
Lynch Brian Joseph SVP and General Counsel
Sold at will 2×
$393.96K 1,800 at 218.87
10.7%
Not planned
30 Nov 2023
Lynch Brian Joseph SVP and General Counsel
Sold at will 3×
$613.73K 3,000 at 204.58
16.7%
Not planned
29 Nov 2023
Lynch Brian Joseph SVP and General Counsel
Sold at will 2×
$796.75K 4,000 at 199.19
21.1%
Not planned
21 Nov 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 20×
$12.13M 64,350 at 188.47
4.0%
Largest buy in 3 yrs
20 Nov 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 12×
$3.85M 20,709 at 185.74
1.3%
17 Nov 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 18×
$8.10M 46,370 at 174.70
3.0%
15 Nov 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 2×
$2.46M 15,199 at 161.97
1.0%
14 Nov 2023
BAKER BROS. ADVISORS LP Director · indirect
Bought 14×
$11.15M 71,848 at 155.15
4.9%
Largest buy in 3 yrs
Showing 51–100 of 129. ← Newer Page 2 of 3 Older →